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In this study we screened twelve newly synthesised N-(substituted phenyl)-2-chloroacetamides for antimicrobial potential 
relying on quantitative structure-activity relationship (QSAR) analysis based on the available cheminformatics prediction 
models (Molinspiration, SwissADME, PreADMET, and PkcSM) and verified it through standard antimicrobial testing 
against Escherichia coli, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), and Candida albicans. Our 
compounds met all the screening criteria of Lipinski’s rule of five (Ro5) as well as Veber’s and Egan’s methods for 
predicting biological activity. In antimicrobial activity tests, all chloroacetamides were effective against Gram-positive 
S. aureus and MRSA, less effective against the Gram-negative E. coli, and moderately effective against the yeast C. 
albicans. Our study confirmed that the biological activity of chloroacetamides varied with the position of substituents 
bound to the phenyl ring, which explains why some molecules were more effective against Gram-negative than Gram-
positive bacteria or C. albicans. Bearing the halogenated p-substituted phenyl ring, N-(4-chlorophenyl), N-(4-fluorophenyl), 
and N-(3-bromophenyl) chloroacetamides were among the most active thanks to high lipophilicity, which allows them 
to pass rapidly through the phospholipid bilayer of the cell membrane. They are the most promising compounds for further 
investigation, particularly against Gram-positive bacteria and pathogenic yeasts.
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The growing spread and resistance of various pathogens 
call for developing new promising antimicrobial agents. 
One such group of agents that have received attention due 
to a wide variety of biological activities (such as analgesic, 
antipyretic, antimicrobial, bactericidal, fungicidal, 
hypoglycaemic, and antitumor) and applications in 
agriculture are chloroacetamides (1–10). Their biological 
activity is driven primarily by their chemical structure, i.e. 
the type of functional groups that bind to active sites on 
receptors of bacterial and fungal strains and promote desired 
intermolecular interactions. Knowing the relation between 
specific structures and their activity allows us to predict the 
biological activity of newly synthesised structures. As there 
is ample evidence (1–18) that N-substituted chloroacetamides 
are highly effective and selective as microbial reagents, we 
were encouraged to develop new N-(substituted phenyl)-
2-chloroacetamide analogues (19) (Figure 1) with an aim 
to improve their selectivity, lipophilicity, and antimicrobial 
activity. This study is therefore an extension on a series of 
newly  syn thes i sed  N- ( subs t i tu ted  phenyl ) -2-
chloroacetamides with the aim to determine how the 
chemical structure of their substituted functional residues 
contributes to their antimicrobial activity.
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Figure 1 Structural formula of the investigated N-(substituted 
phenyl)-2-chloroacetamides
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To do that, we applied quantitative structure-activity 
relationship (QSAR) analysis as well as Lipinski’s rule of 
five (Ro5) (20) and its extensions such as Veber’s (21) and 
Egan’s (22) methods. The assessment of biological activity 
took into account molecular descriptors, biophysiochemical 
properties, and biophysical-kinetic parameters. In addition, 
the synthesised derivatives were evaluated in vitro for 
antimicrobial activity against some of the most common 
pathogens.
MATERIALS AND METHODS
Synthesis of N-(substituted phenyl)-2-chloroacetamides
N-(substituted phenyl)-2-chloroacetamides – namely 
N-phenyl chloroacetamide (SP1), N-(4-methylphenyl) 
ch loroace tamide  (SP2) ,  N - (4-metoxylphenyl ) 
chloroacetamide (SP3), N-(4-chlorophenyl) chloroacetamide 
(SP4), N-(4-bromophenyl) chloroacetamide (SP5), N-(4-
fluorophenyl) chloroacetamide (SP6), N-(4-iodophenyl) 
chloroacetamide (SP7), N-(4-acetylphenyl) chloroacetamide 
(SP8), N-(4-hydroxyphenyl) chloroacetamide (SP9), N-(4-
cyanophenyl) chloroacetamide (SP10), N-(3-cyanophenyl) 
chloroacetamide (SP11), and N-(3-bromophenyl) 
chloroacetamide (SP12) – were synthesised following the 
method described in our earlier article (19).
Characterisation methods and spectral analysis
The chemical structure and purity of the synthesised 
compounds were verified by melting point, Fourier-
transform infrared (FTIR), and 1H and 13C nuclear magnetic 
resonance (NMR) spectroscopy. FTIR spectra were 
recorded in transmission mode using a Bomem MB 100 
(ABB Bomem Inc., Quebec, Canada) spectrometer. 1H and 
13C NMR spectra were determined in deuterated 
dimethylsulphoxide (DMSO-d6), used as the solvent, and 
recorded on a Bruker AC-250 spectrometer (Bruker 
Corporation, Billerica, MA, USA) at 200 MHz using 
tetramethylsilane (TMS) as internal standard. Chemical 
shifts were determined with respect to distorsionless 
enhancement by polarisation transfer (DEPT), two-
dimensional 1H to 13C heteronuclear correlation (HETCOR), 
and selective insensitive nuclei enhancement by polarisation 
transfer (INEPT) long-range experiments and are expressed 
in ppm with respect to TMS (δH=0 ppm) in the 1H NMR 
spectra and to residual solvent signal (δC=39.5 ppm) in the 
13C NMR spectra. Full spectral characterisation of all 12 
chloroacetamides is given in Tables 1–3.
QSAR analysis
Molecular descriptors, i.e. molecular weight (MW), 
hydrogen bond donor (HBD), hydrogen bond acceptor 
(HBA), molecular hydrophobicity/partition coefficient 
(logP), number of rotatable bonds (Nrot), and topological 
polar surface area (TPSA) of the twelve synthesised 
chloroacetamides were obtained using the available 
computational web tools, namely Molinspiration (23) and 
SwissADME (24), while their biophysical-kinetic 
parameters related to absorption and metabolism were 
obtained using SwissADME (24), PreADMET (25), and 
PkcSM (26) designed to predict absorption, distribution, 
metabolism, excretion (ADME) and bioactivity of tested 
molecules.
Microbial strains and growth conditions
Antibacterial activity was tested against Escherichia 
coli ATCC 25922, Staphylococcus aureus ATCC 25923, 
and methicillin resistant S. aureus (MRSA) ATCC 33591 
and antifungal activity against Candida albicans ATCC 
10231. The bacterial strains were cultured in the Luria-
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Table 1 Melting point and yield of N-(substituted phenyl) chloroacetamides
Compound Substituent Melting point (ºC) Yield (%)
SP1 H 136–137 86
SP2 4-CH3 160–162 89
SP3 4-OCH3 117–119 84
SP4 4-Cl 166–168 65
SP5 4-Br 178–180 88
SP6 4-F 128–130 83
SP7 4-I 192–195 72
SP8 4-CH3CO 144–145 64
SP9 4-OH 144–146 76
SP10 4-CN 180–183 56
SP11 3-CN 165–170 61
SP12 3-Br 110–113 83
SP1 – N-phenyl chloroacetamide; SP2 – N-(4-methylphenyl) chloroacetamide; SP3 – N-(4-metoxylphenyl) chloroacetamide; SP4 – 
N-(4-chlorophenyl) chloroacetamide; SP5 – N-(4-bromophenyl) chloroacetamide; SP6 – N-(4-fluorophenyl) chloroacetamide; SP7 – 
N-(4-iodophenyl) chloroacetamide; SP8 – N-(4-acetylphenyl) chloroacetamide; SP9 – N-(4-hydroxyphenyl) chloroacetamide; SP10 
– N-(4-cyanophenyl) chloroacetamide; SP11 – N-(3-cyanophenyl) chloroacetamide; SP12 – N-(3-bromophenyl) chloroacetamide
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Bertani (LB) medium (HiMedia, Mumbai, India) and C. 
albicans in tryptic soy broth (TSB) (Biomedics, Madrid, 
Spain). The bacterial strains and the yeast were cultured 
overnight at 37 °C. Suspensions were adjusted to 0.5 
McFarland standard turbidity (BioMérieux, Marcy-l’Étoile, 
France), which corresponds to 108 CFU/mL.
MIC assay
Minimum inhibitory (MIC), minimum bactericidal 
(MBC), and minimum fungicidal concentrations (MFC) for 
the 12 N-(substituted phenyl)-2-chloroacetamides (SP1–12) 
were determined using the broth microdilution method. The 
final concentration of each sample in the first well was 
4000 µg/mL, while the concentration of the solvent 
dimethyl sulphoxide (DMSO) was 5 %. Twofold serial 
dilutions of the chloroacetamide samples were made with 
LB and TSB in 96-well microtitre plates in the concentration 
range from 32 to 4000 µg/mL. Besides negative control 
(untreated bacteria and fungi) we also used sterility control 
(containing only the culture medium) and positive control, 
treated with rifampicin and nystatin. The final concentration 
of rifampicin and nystatin in the first well was 400 and 
2000 µg/mL, respectively. Each well, except for the sterility 
control, was inoculated with 20 µL of bacterial and yeast 
culture (1×108 CFU/mL), reaching a final volume of 
200 µL. At the end, 22 µL of resazurin (oxidation-reduction 
indicator of cell growth) was added to each well. The plates 
were incubated at 37 °C for 24 h. All tests were performed 
in a lighted environment, but the plates were incubated in 
the dark. Resazurin is a blue non-fluorescent and non-toxic 
dye that becomes pink and fluorescent when reduced to 
resorufin by oxidoreductases from viable cells (27). MIC 
was determined as no change in colour. MBC and MFC, 
which were obtained by sub-culturing test dilutions from 
each well without colour change on agar plates and 
incubating them for 24 h, corresponded to the lowest 
concentration that showed no bacterial or yeast growth. The 
results were expressed in µg/mL.
Statistical analysis
For the analysis of variance (ANOVA) we used the 
Kolmogorov-Smirnov test for the normality of residuals 
and Levene’s test for homogeneity of variance. For mean 
separation for MIC, MBC, and MFC we used Tukey’s 
honest significant difference (HSD) test. Significance was 
set at P<0.05. All dilutions were tested in duplicate with 
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Table 2 Characterisation of investigated N-(substituted phenyl)-2-chloroacetamides
Comp R IR (KBr) νmax (cm-1)
SP1 H 3267 (N-H); 3207, 3145, 3098 (C-H aromatic ring); 2947 (C-H); 1671 (C=O); 1618 (C=C); 1557 (N-H deformation); 1498, (C-H bending); 1443 (C-H bending); 1344 (C-H); 1251 (C-N); 749 (N-H).
SP2 4-CH3
3273 (N-H); 3204, 3135, 3090 (C-H aromatic ring); 2954 (C-H); 1673 (C=O); 1616 (C=C); 1554 
(N-H); 1402 (C-H); 1343 (C-H); 1251 (C-N); 818 (N-H).
SP3 4-OCH3
3295 (N-H); 3139, 3073 (C-H aromatic ring); 2957 (C-H); 2909 2835 (C-H); 1663 (C=O); 1612 
(C=C); 1547 (N-H); 1510 (N-H); 1465 (C-H); 1413 (C-H); 1247 (C-N); 830 (N-H).
SP4 4-Cl 3264(N-H); 3199, 3131, 3082 (C-H aromatic ring); 3005, 2952(C-H); 1669 (C=O); 1614 (C=C); 1551 (N-H); 1490 (C-H); 1400 (C-H); 1248 (C-N); 825 (N-H).
SP5 4-Br 3263 (N-H); 3194 (C-H); 3125, 3077 (C-H aromatic ring); 3000 2953 (C-H); 1669 (C=O); 1549 (N-H); 1488 (C-H); 1395 (C-H); 1248 (C-N); 822 (N-H).
SP6 4-F 3275, 3221 (N-H); 3165 (C-H aromatic ring); 2947 (C-H); 1668 (C=O); 1508 (N-H); 1406 (C-H); 1292; 1212 (C-N); 832 (N-H).
SP7 4-I 3309, 3270 (N-H); 3194, 3077 (C-H aromatic ring); 2936 (C-H); 2953 (C-H); 1672 (C=O); 1610 (N-H); 1543 (C-H); 1392–1089 (CH); 1245 (C-N); 817 (N-H).
SP8 4-COCH3
3325, 3286 (N-H); 3196, 3109 (C-H aromatic ring); 2922, 2857 (C-H); 1707 (C=O); 1655 (C=C); 
1599 (N-H); 1539 (C-H); 1283 (C-O); 1252 (C-N); 834 (N-H).
SP9 4-OH 3296 (O-H); 3144 (N-H); 3098 (C-H); 1677 (C=O); 1508 (N-H); 1313 (C-H); 1211 (C-N); 820 (N-H).
SP10 4-CN 3265 (N-H); 3192, 3119 (C-H); 2946 (C-H); 2226 (C?N); 1681 (C=O); 1603 (C=C); 1539 (N-H); 1408, 1345 (C-H); 1256 (C-N); 839 (N-H).
SP11 3-CN 3265 (N-H); 3096 (C-H); 2964 C-H); 2232 (C?N); 1678 (C=O); 1610 (C=C); 1561 (N-H); 1485 (C-H); 1293 (C-N); 1089 (C-H); 799 (N-H).
SP12 3-Br 3268 (N-H); 3193, 3127 (C-H); 2945 (C-H); 1679 (C=O); 1594 (N-H); 1424 (C-H); 1249 (C-N); 779 (N-H).
SP1 – N-phenyl chloroacetamide; SP2 – N-(4-methylphenyl) chloroacetamide; SP3 – N-(4-metoxylphenyl) chloroacetamide; SP4 – 
N-(4-chlorophenyl) chloroacetamide; SP5 – N-(4-bromophenyl) chloroacetamide; SP6 – N-(4-fluorophenyl) chloroacetamide; SP7 – 
N-(4-iodophenyl) chloroacetamide; SP8 – N-(4-acetylphenyl) chloroacetamide; SP9 – N-(4-hydroxyphenyl) chloroacetamide; SP10 
– N-(4-cyanophenyl) chloroacetamide; SP11 – N-(3-cyanophenyl) chloroacetamide; SP12 – N-(3-bromophenyl) chloroacetamide
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Table 3 1H and 13C NMR spectral data
N-phenyl chloroacetamide
(SP1)
1H NMR (CDCl3): δ 4.272 (2H, s, Cl-CH2), 7.057–7.130 (1H, t, JHH = 7.4 Hz, Ar-
4H), 7.302–7.380 (2H, t, JHH = 7.8 Hz, Ar-H), 7.597–7.636 (2H, d, JHH = 7.8 Hz, 
Ar-H), 10.321 (1H, s, NH). 13C NMR (CDCl3): δ 43.833 (Cl-CH2), 119.651 (C2,C5), 




1H NMR (CDCl3): δ 2.255 (2H, s, CH3), 4.421 (1H, s, Cl-CH2), 7.111–7.153 (2H, 
d, JHH = 8.2 Hz, Ar-H), 7.473–7.515 (2H, d, JHH = 8.2 Hz, Ar-H), 10.222 (1H, s, 
NH). 13C NMR (CDCl3): δ 20.655 (CH3), 43.797 (Cl-CH2), 119.614 (C2,C6), 129.483 




1H NMR (CDCl3): δ 3.729 (2H, s, OCH3), 4.229 (1H, s, Cl-CH2), 6.886–6.948 (2H, 
d, JHH = 9.0 Hz, Ar-H), 7.481–7.560 (2H, d, JHH = 9.0 Hz, Ar-H), 10.177 (1H, s, 
NH).). 13C NMR (CDCl3): δ 43.742 (Cl-CH2), 55.359 (OCH3), 114.189 (C3,C5), 




1H NMR (CDCl3): δ 4.280 (1H, s, Cl-CH2), 7.358–7.431 (2H, d, JHH = 9.0 Hz, Ar-H), 
7.613–7.686 (2H, d, JHH = 9.0 Hz, Ar-H), 10.445 (1H, s, NH), 13C NMR (CDCl3): δ 




1H NMR (CDCl3): δ 4.274 (1H, s, Cl-CH2), 7.495–7.616 (4H, m, Ar-H), 10.447 
(1H, s, N-H). 13C NMR (CDCl3): δ 43.742 (Cl-CH2), 115.736 (C4), 121.526 (C2,C6), 
131.923 (C3,C5), 138.095 (C1), 165.061 (C=O).
N-(4-fluorophenyl) chloroacetamide
(SP6)
1H NMR (CDCl3): δ 4.369 (1H, s, Cl-CH2), 7.122–7.226 (2H, t, JHH = 9.0 Hz, Ar-
H)), 7,588–7,675 (2H, m, Ar-H), 10,337 (1H, s, NH). 13C NMR (CDCl3): δ 43.688 




1H NMR (CDCl3): δ 4.263 (1H, s, Cl-CH2), 7.425–7.4709 (2H, d, JHH = 9.0 Hz, Ar-
H), 7,658–7,701 (2H, d, JHH = 9.0 Hz, Ar-H), 10.416 (1H, s, NH). 13C NMR (CDCl3): 




1H NMR (CDCl3): δ 2.544 (3H, s, CH3), 4.328 (1H, s, Cl-CH2), 7,723–7,768 (2H, 
d, JHH = 9.0 Hz, Ar-H), 7.945–7.990 (2H, d, JHH = 9.0 Hz, Ar-H), 10.646 (1H, s, 
NH). 13C NMR (CDCl3): δ 26.645 (CH3), 43.833 (Cl-CH2), 118.868 (C2,C6), 129.793 
(C3,C5), 132.451 (C4), 143.030 (C1), 165.462 (C=O), 196.798 (COCH3).
N-(4-hydroxyphenyl) 
chloroacetamide (SP9)
1H NMR (CDCl3): δ 4.280 (2H, s, Cl-CH2), 4.684 (1H, s, OH), 7.139–7.184 (2H, d, 
JHH = 9.0 Hz, Ar-H), 7.625–7.686 (2H, d, JHH = 8.8 Hz, Ar-H). 13C NMR (CDCl3): 




1H NMR (CDCl3): δ 4.319 (2H, s, Cl-CH2), 7.552–7.619 (2H, d, JHH = 9.0 Hz, Ar-H), 
7.782–7.877 (2H, d, JHH = 9.0 Hz, Ar-H), 10.745 (1H, s, 2-H). 13C NMR (CDCl3): δ 
43.669 (Cl-CH2), 111.985 (C3), 118.668 (CN), 122.309 (C2), 124.203 (C6), 127.662 
(C4), 130.321–130.594 (C5), 139.516 (C1), 165.589 (C=O).
N-(3-cyanophenyl) chloroacetamide
(SP11)
1H NMR (CDCl3): δ 4.339 (1H, s, Cl-CH2), 7.552–7.619 (2H, d, JHH = 5.6 Hz, Ar-
H), 7.782–7.813 (1H, m, Ar-H), 8.094 (1H, s, Ar-H), 10.745 (1H, s, NH). 13C NMR 
(CDCl3): δ 43.669 (Cl-CH2), 111.985 (C3), 118.668 (CN), 122.309 (C2), 124.203 




1H NMR (CDCl3): δ 4.286 (3H, s, Cl-CH2), 7.285–7.358 (2H, m, Ar-H), 7.470–
7.571 (1H, m, Ar-H), 7.962 (1H, s, Ar-H), 10.489 (1H, s, N-H). 13C NMR (CDCl3): 
δ 43.688 (Cl-CH2), 118.376 (C2), 121.836 (C5), 121.927 (C6), 126.697 (C4), 131.067 
(C3), 140.262 (C1), 165.243 (C=O).
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three repetitions. Statistical analyses were run on 
STATISTICA v.7 (StatSoft, Inc., Tulsa, OK, USA) and IBM 
SPSS Statistics v.20 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Biological profile of N-(substituted phenyl)-2-
chloroacetamides
Table 4 shows that compounds containing the 4-COCH3 
(SP8), 4-OH (SP9), 3-CN (SP10), and 4-CN (SP11) groups 
within the phenyl core had their TPSA in the optimal 
interval from 46.17 to 52.89 Å2, which is the most 
favourable for high permeability. N-(4-bromophenyl)-2-
chloroacetamoide (SP5) showed the highest lipophilicity, 
and the compound carrying the p-OH-substituent (SP9) the 
lowest (Table 5).
The best predisposition for optimal intestinal absorption 
was seen in the derivatives containing electron-donor 
substituent (compound SP3) and strong electron-acceptor/
halogen substituents (compounds SP8 and SP10–12), and 
these properties were significantly higher than those 
observed for commercial drugs levetiracetam and piracetam 
(Table 6).
The above mentioned web tools Molinspiration (23), 
SwissADME (24), PreADMET (25), and PkcSM (26) 
predicted that the investigated chloroacetamides would not 
significantly inhibit the activity of P-glycoprotein (P-gp or 
ABCB1) (Table 7). Regarding CYP450 inhibition, CYP1A2 
showed the highest probability to be inhibited by all tested 
chloroacetamides.
Antimicrobial activity
Table 8 shows the results of antibacterial and antifungal 
activity of the tested chloroacetamides. DMSO, which was 
used as negative/solvent control, did not show any 
inhibitory effect on the tested strains. The most sensitive 
strains, with MIC mainly lower than 100 µg/mL, were S. 
aureus and MRSA. The MIC of most compounds ranged 
between 40 and 130 µg/mL for these pathogens and did not 
significantly differ from rifampicin. N-(4-iodophenyl) 
chloroacetamide (SP7) showed the strongest activity against 
both Gram-positive strains (MIC 40 µg/mL). E. coli was 
the most resistant strain, as the MIC of half of the tested 
compounds (SP1, SP2, SP4, SP5, SP7, and SP11) ranged 
from 920 to 4000 µg/mL. All compounds save for SP1 and 
SP11 were significantly less effective than rifampicin.
The yeast strain C. albicans showed moderate 
susceptibility to chloroacetamides compared to Gram-
positive bacterial strains, with MICs mostly below 500 µg/
mL, but much higher than to positive control nystatin, with 
the MIC of 2000 µg/mL. Only N-(4-hydroxyphenyl) 
chloroacetamide (SP9) had a higher MIC of 2660 µg/mL. 
The best and statistically significant inhibitory activity vs 
nystatin against C. albicans was observed for SP4, SP6, 
and SP12, with MICs ranging from 60 to 100 µg/mL and 
similar to the one against Gram-positive bacterial strains. 
In general, N-(4-cyanophenyl) chloroacetamide (SP10) 
showed significant inhibitory activity (lowest MICs) against 
all tested bacterial strains and yeast taken together. SP4 and 
SP12 showed the strongest inhibitory activity against C. 
albicans and Gram-positive strains. It is interesting to note 






















SP1 169.61 11 3 1 2 45.55 29.10
SP2 183.63 12 3 1 2 50.52 29.10
SP3 199.63 13 4 1 3 52.04 38.33
SP4 204.05 12 3 1 2 50.56 29.10
SP5 248.50 12 3 1 2 53.25 29.10
SP6 187.60 12 3 1 2 45.51 29.10
SP7 295.50 12 3 1 2 58.27 29.10
SP8 211.64 14 4 1 3 55.75 46.17
SP9 185.61 12 3 2 3 47.57 49.33
SP10 194.62 13 3 1 3 50.27 52.89
SP11 194.62 13 3 1 3 50.27 52.89
SP12 248.50 12 3 1 3 53.25 29.10
Levetiracetam 156.23 11 3 1 2 48.17 46.33
Piracetam 142.16 10 2 1 2 38.76 63.40
SP1 – N-phenyl chloroacetamide; SP2 – N-(4-methylphenyl) chloroacetamide; SP3 – N-(4-metoxylphenyl) chloroacetamide; SP4 – 
N-(4-chlorophenyl) chloroacetamide; SP5 – N-(4-bromophenyl) chloroacetamide; SP6 – N-(4-fluorophenyl) chloroacetamide; SP7 – 
N-(4-iodophenyl) chloroacetamide; SP8 – N-(4-acetylphenyl) chloroacetamide; SP9 – N-(4-hydroxyphenyl) chloroacetamide; SP10 
– N-(4-cyanophenyl) chloroacetamide; SP11 – N-(3-cyanophenyl) chloroacetamide; SP12 – N-(3-bromophenyl) chloroacetamide
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Table 5 Partition coefficients of the studied chloroacetamides
Compound logP (22) logPo/w(XLOGP3) (23) logPo/w(WLOGP) (23) logPo/w(MLOGP) (23)
SP1 1.72 1.63 1.67 1.84
SP2 2.17 1.99 1.98 2.15
SP3 1.78 1.65 1.68 1.54
SP4 2.40 2.26 2.33 2.42
SP5 2.53 2.32 2.44 2.56
SP6 1.89 1.73 2.23 2.27
SP7 2.81 2.28 2.28 2.71
SP8 1.62 1.86 1.88 1.47
SP9 1.24 1.27 1.38 1.23
SP10 1.45 1.82 1.54 1.18
SP11 1.48 1.35 1.54 1.18
SP12 2.51 2.93 2.44 2.56
Levetiracetam 0.69 0.62 -0.03 0.28
Piracetam -1.32 -1.54 -1.29 -0.96
SP1 – N-phenyl chloroacetamide; SP2 – N-(4-methylphenyl) chloroacetamide; SP3 – N-(4-metoxylphenyl) chloroacetamide; SP4 – 
N-(4-chlorophenyl) chloroacetamide; SP5 – N-(4-bromophenyl) chloroacetamide; SP6 – N-(4-fluorophenyl) chloroacetamide; SP7 – 
N-(4-iodophenyl) chloroacetamide; SP8 – N-(4-acetylphenyl) chloroacetamide; SP9 – N-(4-hydroxyphenyl) chloroacetamide; SP10 
– N-(4-cyanophenyl) chloroacetamide; SP11 – N-(3-cyanophenyl) chloroacetamide; SP12 – N-(3-bromophenyl) chloroacetamide
Table 6 QSAR pharmacokinetic profiles of the selected compounds related to absorption properties
Compound




















is a P-gp 
inhibitor
SP1 High 91.156 Yes 0.902206 No No
SP2 High 91.692 Yes 2.16896 No No
SP3 High 93.810 Yes 0.612824 No No
SP4 High 91.969 Yes 1.65555 No No
SP5 High 91.902 Yes 1.79202 No No
SP6 High 91.217 Yes 1.07913 No No
SP7 High 90.802 Yes 1.52595 No No
SP8 High 92.635 Yes 0.546121 No No
SP9 High 90.745 Yes 0.975597 No No
SP10 High 92.986 Yes 0.975597 No No
SP11 High 92.817 Yes 0.975597 No No
SP12 High 92.405 Yes 1.79204 No No
Levetiracetam High 86.852 No 0.440234 No No
Piracetam High 86.061 No 0.165163 No No
SP1 – N-phenyl chloroacetamide; SP2 – N-(4-methylphenyl) chloroacetamide; SP3 – N-(4-metoxylphenyl) chloroacetamide; SP4 – 
N-(4-chlorophenyl) chloroacetamide; SP5 – N-(4-bromophenyl) chloroacetamide; SP6 – N-(4-fluorophenyl) chloroacetamide; SP7 – 
N-(4-iodophenyl) chloroacetamide; SP8 – N-(4-acetylphenyl) chloroacetamide; SP9 – N-(4-hydroxyphenyl) chloroacetamide; SP10 
– N-(4-cyanophenyl) chloroacetamide; SP11 – N-(3-cyanophenyl) chloroacetamide; SP12 – N-(3-bromophenyl) chloroacetamide
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that SP7 and SP9, which strongly inhibited Gram-positive 
strains, were completely ineffective against C. albicans.
MICs for rifampicin control were in the range evidenced 
for most chloroacetamides against Gram-positive strains, 
and quite lower against E. coli. Chloroacetamide MBCs 
and MFCs were at least twice as high as their MICs, varying 
from 120 to over 4000 µg/mL in the case of MBCs for SP4 
and SP5 against E. coli, which was the highest concentration 
we applied in testing (Table 8).
DISCUSSION
Predicting biological activity of newly synthesised small 
molecules to be screened for medicinal use takes into 
account simple molecular properties such as molecular 
weight and the number of hydrogen/rotatable bonds, which 
determine the size, polarity, and flexibility of a compound 
(28, 29). The most common screening criterion is Lipinski’s 
rule of five (Ro5). Its name stems from the following 
cheminformatics filters: MW≤500 g/mol, number of 
HBD≤5, number of HBA≤10, and logP≤5), whose aim is 
to filter out compounds that do not satisfy the most common 
oral absorption parameters. Although it does not predict 
whether a compound will be biologically active, Ro5 does 
not allow more than one deviation from the set parameters 
(20). This rule was later extended by other empirical 
thresholds for potential bioactivity, such as those proposed 
by Veber (21) (Nrot≤10, TPSA≤140 Å2, number of HBD/
HBA≤12) and Egan (22) (WlogP≤5.88 and TPSA≤131.6 Å2).
Chloroacetamides synthesised and tested in our study 
met all of these criteria (Tables 4 and 5). The introduction 
of a p-substituted phenyl ring and the chlorine atom into 
the acetamide fragment increased the molecular weight of 
the synthesised compounds compared to commercial 
levetiracetam and piracetam, and their topological polar 
surface area in the range of 29.10–52.89 Å2 and the number 
of rotatable bonds not exceeding 4 promise good biological 
activities (30). Veber (31) demonstrated that molecules with 
TPSA≤140 Å2 display efficient permeability. Higher 
partition coefficient logP will allow biologically active 
chloroacetamides higher efficiency by passive diffusion as 
well as effective binding to the active receptor sites (32). 
Besides, almost no divergence in logP (-Br, -CN) was 
observed for compounds with the same substituent in 
different posit ions (3).  Likewise,  all  analysed 
chloroacetamide molecules showed higher absorption 
probability (Table 3) thanks to small size and low polarity 
(29).
In antimicrobial activity tests, all N-(substituted 
phenyl)-2-chloroacetamides were effective against Gram-
positive bacteria, less effective against the Gram-negative 
E. coli, and moderately effective against the C. albicans 
yeast (Table 8). This was expected, given the differences 
in the cell wall structure and composition of these species. 
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presence of electron withdrawing groups (–Br, –Cl, –NO2) 
at the ortho, meta, and para-position of the ring B and to 
N-acylation with the synthesised compounds. Another study 
(34) indicated high activity of 2-(2-methylquinoxalin-3-
yl thio)-N-(benzo[d]thiazol-2-yl)acetamide and 
2-(2-methylquinoxalin-3-ylthio)–N-cyclohexylacetamide 
against E. coli, S. aureus, and C. albicans.
Compounds SP1–SP6, SP9, SP10, and SP12 showed 
the highest antimicrobial activity in our study, much thanks 
to their structure (lipophilicity/hydrophobicity) and no more 
than one hydrogen or nitrogen atom (35). Higher logP 
values may have facilitated their penetration through the 
bacterial/fungal cell membrane and microbial death. Good 
biological activity of SP4–SP7 and SP12 can also be 
attributed to the presence of halogenated substituents (3, 
36).
Jablonkai et al. (37) demonstrated that the biological 
activity of chloroacetamides varies with the position of 
effects of organic acetamide derivatives N-(2-hydroxy-
4 ( o r 5 ) - n i t r o / a m i n o p h e n y l )  b e n z a m i d e s  a n d 
phenylacetamides, whose structure differs from our 
compounds. Their MICs (around 250 µg/mL) were higher 
than ours against C. albicans and E. coli and similar against 
S. aureus. Similar findings were reported by a study of 
biologically active 2-chloro-N-alkyl/aryl acetamide 
derivatives (12). However, as neither study tested their 
respective compounds against MRSA, ours seems to be the 
first in this respect. More recently, Sharma et al. (33) 
ident i f ied 2-((4-bromophenyl)amino)-N - (4-(4-
bromophenyl) thiazol-2-yl)acetamide,  N - (4-(4-
bromophenyl) thiazol-2-yl)-2-((4-chloro-3-nitrophenyl)
amino)acetamide, and N-(4-(4-bromophenyl)thiazol-2-yl)-
2-((2-chloro-4-nitrophenyl)amino)acetamide as effective 
against S. aureus, E. coli, and C. albicans, with the lowest 
MICs ranging from 13 to 27 µmol/L. They also reported 
that the improved antimicrobial activity was owed to the 




C. albicans E. coli S. aureus MRSA
MIC (µg/mL)
SP1 4-H 190±40c 920±80c 90±20c 50±0cd
SP2 4-CH3 330±110
c 3330±330ab 60±0c 60±0cd
SP3 4-OCH3 190±40
c 540±110c 110±10c 190±40bc
SP4 4-Cl 60±0c 3670±330ab 60±0c 90±20bcd
SP5 4-Br 330±80c 4000±0a 60±0c 60±0cd
SP6 4-F 110±10c 500±140c 150±50bc 110±10bcd
SP7 4-I 830±170c 2670±330b 40±10c 40±10d
SP8 4-COCH3 330±80
c 330±80c 190±40bc 90±20bcd
SP9 4-OH 2660±670a 270±20c 130±0c 40±10d
SP10 3-CN 290±40c 190±40c 40±10c 90±20bcd
SP11 4-CN 230±20c 1000±290c 750±140a 220±20ab
SP12 3-Br 100±20c 500±140c 80±20c 90±20bcd
Ant/Myc – 2000±0ab 90±10c 40±10c 70±20cd
MBC/MFC (µg/mL)
SP1 4-H 500±0c 2000±0b 250±0bcd 120±0c
SP2 4-CH3 670±170
c 4000±0a 170±40cd 310±110c
SP3 4-OCH3 330±80
c 1000±0c 250±0bcd 330±80c
SP4 4-Cl 2000±0b Nd 130±0d 750±140bc
SP5 4-Br 4000±0a Nd 420±80bcd 750±140bc
SP6 4-F 330±80c 1000±0c 750±140bc 250±0c
SP7 4-I 3000±580ab 4000±0a 130±0d 290±110c
SP8 4-COCH3 670±170
c 670±170d 750±140bc 330±80c
SP9 4-OH 4000±0a 500±0d 330±80bcd 170±40c
SP10 3-CN 500±0c 420±80d 130±0d 250±0c
SP11 4-CN 500±0c 2000±0b 2330±330a 1330±330ab
SP12 3-Br 670±170c 1000±0c 210±40cd 330±80c
Ant/Myc – Nd 130±30e 100±0d 100±0c
*Values followed by the same letter in each column and isolate were not significantly different (P<0.05, Tukey’s HSD test). Ant/Myc 
– rifampicin or nystatin. Nd – not determined (above the highest concentration applied of 4000 µg/mL)
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substituents bound to the phenyl ring. This may explain 
different activity of the compounds SP5 and SP12 or SP10 
and SP11 against the tested strains. Furthermore, different 
susceptibility of the tested pathogens to compound SP10 
may be the consequence of their morphological 
characteristics determining compound penetration into the 
microbial/fungal cell.
CONCLUSION
Judging from the cheminformatics prediction models 
such as Molinspiration, SwissADME, PreADMET, and 
PkcSM, our twelve newly synthesised N-(substituted 
phenyl)-2-chloroacetamides met all the empirical criteria 
for good biological activity. Standard antimicrobial activity 
tests showed they were highly effective against Gram-
positive bacteria, less effective against the Gram-negative 
E. coli, and moderately effective against the C. albicans 
yeast. Bearing the halogenated p-substituted phenyl ring, 
N-(4-chlorophenyl) chloroacetamide, N-(4-fluorophenyl) 
chloroacetamide, and N-(3-bromophenyl) chloroacetamide 
were among the most active thanks to high lipophilicity, 
which allows them to pass rapidly through the phospholipid 
bilayer of the cell membrane. They are the most promising 
compounds for further investigation, particularly against 
Gram-positive bacteria and yeasts. Our findings have set 
the path for the preparation of new, improved N-(p-
substituted phenyl)-2-chloroacetamides and for better 
understanding of the structure-activity relationship, which 
should extend research to more different bacterial and 
fungal strains in the future.
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Karakterizacija dvanaest novosintetiziranih N-(supstituiranih fenil)-2-kloroacetamida s QSAR analizom i 
utvrđivanje njihovih antimikrobnih aktivnosti
U ovom istraživanju analizirano je dvanaest novosintetiziranih N-(supstituiranih fenil)-2-kloroacetamida radi determinacije 
njihova antimikrobnog potencijala u korelaciji s kvantitativnom analizom aktivnosti spojeva i njihove molekularne 
strukture (QSAR analiza). QSAR analiza omogućena je primjenom predikcijskih modela (Molinspiration, SwissADME, 
PreADMET i PkcSM) te je verificirana potvrđenom antimikrobnom aktivnošću sintetiziranih spojeva prema bakterijama 
Escherichia coli, Staphylococcus aureus, na meticilin otporan S. aureus (MRSA) i prema gljivici Candida albicans. 
Novosintetizirani spojevi zadovoljavaju sve predikcijske modele za značajnu potencijalnu biološku aktivnost prema 
kriterijima Lipinskog, Vebera i Egana. Na osnovi određene antimikrobne aktivnosti spojeva, svi kloroacetamidi pokazali 
su učinkovitost prema sojevima gram-pozitivnih bakterija S. aureus i MRSA, neznatno manju učinkovitost prema gram-
negativnoj E. coli i umjerenu učinkovitost prema gljivici C. albicans. Naše je istraživanje potvrdilo potencijal biološke 
aktivnosti kloroacetamida, koji je bilo uvjetovan intenzitetom manifestirane aktivnosti u zavisnosti od pozicije supstituenata 
vezanih za fenilni prsten, što je i razlog značajnije učinkovitosti pojedinih spojeva prema gram-negativnima u odnosu na 
gram-pozitivne bakterije ili gljivicu C. albicans. Budući da imaju halogenirani p-supstituirani fenilni prsten, N-(4-
klorofenil), N-(4-fluorofenil) i N-(3-bromofenil) kloroacetamidi bili su među najaktivnijima zahvaljujući visokoj lipofilnosti, 
koja im omogućava da brzo prolaze kroz fosfolipidni dvosloj stanične membrane. Ovi spojevi najviše obećavaju u daljim 
ispitivanjima, naročito protiv gram-pozitivnih bakterija i patogenih gljivica.
KLJUČNE RIJEČI: N-supstituirani amidi; antimikrobni potencijal; kvantitativna analiza kemijske strukture i aktivnosti 
spojeva
